What is the mechanism of Aminophenazone?

Aminophenazone, also known as aminopyrine, is a non-steroidal anti-inflammatory drug (NSAID) that was widely used for its analgesic, antipyretic, and anti-inflammatory properties. Though its usage has diminished due to safety concerns, understanding its mechanism of action provides insights into the pharmacodynamics of NSAIDs and related compounds.

The primary mechanism of aminophenazone involves the inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes are crucial in the biosynthesis of prostaglandins, which are lipid compounds that play significant roles in inflammation, pain, and fever. By inhibiting COX enzymes, aminophenazone reduces the production of prostaglandins, thereby diminishing inflammation and alleviating pain and fever.

 

Researching Aminophenazone beyond the basics?

Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore Aminophenazone with Hiro LS Researcher →

In detail, aminophenazone interferes with the COX enzymes by blocking the conversion of arachidonic acid to prostaglandin H2, the precursor of various other prostaglandins and thromboxanes. This inhibition leads to decreased levels of prostaglandins E2 and I2, which are primarily responsible for the mediation of inflammation, pain, and fever. 

Beyond COX inhibition, aminophenazone also exerts its effects through its metabolites. One notable metabolite is 4-aminoantipyrine, which retains similar pharmacological activities. The metabolites contribute to the overall therapeutic effects of aminophenazone, extending its duration of action.

However, the use of aminophenazone has been largely discontinued due to its adverse effects, particularly the risk of agranulocytosis, a serious and potentially life-threatening reduction in the number of white blood cells, leading to a compromised immune response. This condition significantly limits the drug's safety profile, prompting the development and preference for safer alternatives.

Despite these risks, the study of aminophenazone has contributed valuable knowledge to the understanding of NSAIDs and their mechanisms. It highlights the importance of COX enzymes in the inflammatory process and underscores the necessity of balancing efficacy with safety in drug development.

In summary, aminophenazone operates primarily through the inhibition of COX enzymes, leading to decreased production of prostaglandins and subsequent reduction in inflammation, pain, and fever. Its historical use and mechanism of action provide a foundational understanding of how NSAIDs function, even as newer and safer medications have replaced it in clinical practice.

Continue your Aminophenazone research with Synapse Hiro LS Researcher

This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.

Questions to explore:

• What is the mechanism of action of Aminophenazone, and which targets or pathways are involved?
• What preclinical and clinical evidence supports the proposed mechanism of Aminophenazone?
• Which clinical trials are evaluating Aminophenazone, and what outcomes have been reported?
• How does Aminophenazone compare with other assets targeting the same pathways or indications?

Ask Synapse Hiro LS Researcher →

AI may make mistakes. Check important info.